In The News

Dominique Hussey in Bloomberg on Canada's Pharmaceutical IP Rules

July 26, 2017
Social Media
Download
Download
Read Mode
Subscribe
Summarize

Dominique Hussey comments in Bloomberg BNA on draft changes to Canada's patent litigation process for prescription drugs. She points out that the changes create new opportunities and challenges, introduce complexity into the litigation and will raise new procedural and substantive issues that have no precedent. The amendments could take effect as early as September 21, 2017, when the Comprehensive Economic Trade Agreement (CETA) that inspired the changes will be provisionally applied.

Social Media
Download
Download
Subscribe
Republication Requests

To obtain permission to republish this publication or any other publication, contact Erica Wirthlin at wirthline@bennettjones.com.

For Informational Purposes Only

This publication provides an overview of trends and legal updates for informational purposes only. For personalized legal advice, please contact the authors.

From the Same Authors

See All
Article

WTR: Trademark Litigation Review 2024

December 12, 2023
Dominique T. Hussey & Melissa M. Dimilta
Article

Winning Strategies for Litigating Before Canadian Courts

November 24, 2023
Dominique T. Hussey & Melissa M. Dimilta
Blog

Data Centre West 2026: Alberta's Digital Infrastructure Moment Has Arrived

September 22, 2026
Larissa D. Lees & Jessica Kennedy
Blog

From Super to Mega: Canada Proposes New "Productivity Mega Deduction" to Spur Investment

September 21, 2026
Greg M. Johnson, Jared A. Mackey & Brendan Sigalet
Blog

Government of Canada Reduces the Scope of the Project List under the Impact Assessment Act

September 11, 2026
Ashley M. White, Martin Ignasiak KC & Nathan Murray